0D8C7EC1-9BFB-44A1-8AF8-05D2A6BBE0F9
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 9.42838370565046
- age_years
- 33
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 167869B6-9620-445E-BA77-B6F95A6463F5 | — | — | 0.918 |
| 2 | 6819D9DA-FE18-4584-8AF6-E53DD894852E | — | — | 0.887 |
| 3 | ERR2598195 | fetal | fetal | 0.883 |
| 4 | 9CC5EB30-A8C2-4FDF-8074-467AA98ED1CA | — | — | 0.881 |
| 5 | 9F204EEA-9026-4367-8586-C2127D55AC5E | — | — | 0.881 |
| 6 | 0730F3DB-384B-43E6-A69F-BF3F7C2CCE78 | — | — | 0.880 |
| 7 | ERR2598213 | fetal | fetal | 0.869 |
| 8 | TCGA-BH-A0HL-01A-11R-A10U-07 | — | B | 0.869 |
| 9 | E3818BAA-BA28-4CE4-A745-BB3692883888 | — | — | 0.868 |
| 10 | 7DC6D598-8506-4680-81DF-C1D0F1B5C27D | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.437 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.333 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.257 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.241 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.206 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.195 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.158 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.152 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.127 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.098 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.095 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.085 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.043 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.004 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.002 | Idelalisib | — uncovered |